Ithra’s Hijrah: In the Footsteps of the Prophet exhibit revisits the birth of Islam from a modern perspective

DHAHRAN, Saudi Arabia, Aug. 1, 2022 /PRNewswire/ — The King Abdulaziz Center for World Culture (Ithra) is excited to launch Hijrah: In the Footsteps of the Prophet, a research-based artistic retelling of Prophet Mohammad’s  ﷺ journey from Makkah to Madinah. Filling gaps in knowledge on the journey that marked the beginning of the Muslim calendar, the exhibition brings together contemporary and […]

DHAHRAN, Saudi ArabiaAug. 1, 2022 /PRNewswire/ — The King Abdulaziz Center for World Culture (Ithra) is excited to launch Hijrah: In the Footsteps of the Prophet, a research-based artistic retelling of Prophet Mohammad’s  ﷺ journey from Makkah to Madinah. Filling gaps in knowledge on the journey that marked the beginning of the Muslim calendar, the exhibition brings together contemporary and Islamic art and combines it with artefacts, film, performance and more for a first-of-its-kind, immersive and multidisciplinary experience. Hijrah: In the Footsteps of the Prophet is open at Ithra’s iconic building for nine months before traveling around the Kingdom, the region and the world.

Curated by Ithra in collaboration with some of the world’s leading authorities on the Hijrah of the Prophet, the exhibition traces the physical route of Prophet Mohammad’s ﷺ journey to explore its historical significance and bring the human story of the Hijrah to the fore. It is presented in collaboration with partners from key regional and international organizations who have lent pieces, many of which have never been publicly displayed before, to augment key commissioned items for the exhibit. The partners include National Museum of Saudi Arabia, the House of Islamic Arts, the King Abdulaziz Complex for Endowment Libraries and Turquoise Mountain, a Prince of Wales charity supporting arts and heritage. Hijrah: In the Footsteps of the Prophet is Ithra’s first traveling exhibition, set to be exhibited across Saudi Arabia then globally during its five-year run, sharing new perspectives and findings on the story of the Prophet’s journey from Makkah to Madinah.

“As one of the most detailed studies ever of the history and topography of the Hijrah, this exhibition exemplifies Ithra’s wider mission to tell the world’s defining stories through art, heritage, culture and research,” said Abdullah Al Rashid, Director of Ithra. “The exhibit looks at the history and the legacy of the event from different perspectives, including science, physical geography, material culture, theology, art and cultural memory. This exhibition represents significant advances in academic research around the history of Islam while its focus on the human story surrounding the journey and our shared human values will also promote greater understanding, empathy and tolerance.”

For more information on Ithra and its programs, visit www.ithra.com.

Photo – https://mma.prnewswire.com/media/1870161/Hijrah_Exhibit.jpg

Vantage partners UNHCR for global fundraising activity for refugees, matches donations dollar-for-dollar.

SINGAPORE, Aug. 1, 2022 /PRNewswire/ — Vantage, an international multi-asset broker, is pleased to announce that it is launching a month-long donation drive in support of UNHCR, the UN Refugee Agency, to help refugees and internally displaced persons worldwide. Vantage will be matching all donations from both new and existing clients, dollar for dollar, to support humanitarian […]

SINGAPORE, Aug. 1, 2022 /PRNewswire/ — Vantage, an international multi-asset broker, is pleased to announce that it is launching a month-long donation drive in support of UNHCR, the UN Refugee Agency, to help refugees and internally displaced persons worldwide.

Vantage partners UNHCR for global fundraising activity for refugees, matches donations dollar-for-dollar.

Vantage will be matching all donations from both new and existing clients, dollar for dollar, to support humanitarian efforts undertaken by UNHCR. The donation drive will run for one month until 30 August and may be extended based on client feedback.

UNHCR is a global organisation that has spent the last 70 years dedicated to saving lives, protecting rights and building a better future for refugees. Vantage and UNHCR jointly believe that everyone has the right to seek asylum and find safe refuge.

According to UNHCR, the number of people forced to flee conflict, violence, human rights violations, and persecution has now crossed the staggering milestone of 100 million for the first time on record, highlighting worldwide food insecurity, the climate crisis and other emergencies from Africa to Afghanistan as leading causes.

Ann Moey, Partnerships Manager at UNHCR says, “International solidarity is needed now more than ever, and all sectors of society can do their bit to help. Support from private sector partners like Vantage helps us inject vital energy into our humanitarian efforts, and allows us to deliver more assistance to vulnerable, displaced communities worldwide.”

The fundraising initiative is another step forward in Vantage’s corporate ESG journey, which was driven by the collective desire among its staff to make the world a better place. This donation drive follows closely after Vantage’s partnership with Supercar Blondie in participating in the Blue Carbon ESG initiative in Sardinia, Italy, as well as its multi-year sponsorship of the McLaren MX Extreme E team.

Sofiia Starchevska, ESG Ambassador at Vantage, said, “It’s infinitely more empowering and motivating knowing that your actions are one of many. It’s easier to see the power of collective, as opposed to individual, action, and this is what we want to achieve with this fundraising activity.”

“At Vantage, we know that the mental, emotional, and physical trauma of being displaced and having to rebuild in a strange land is a massive challenge, and we hope our initiative will double our support for refugees to seek protection and enable them to rebuild their lives. Together with UNHCR, we hope to make care our shared currency.”

For more information about our fundraising programme, please visit:
https://donate.unhcr.org/sg/en-sg/vantage

About Vantage

Vantage is a global, multi-asset broker offering clients access to a nimble and powerful service for trading CFDs on Forex, Commodities, Indices, and Shares.

With more than 10 years of market experience. Vantage now has over 1,000 employees/personnel across more than 30 global offices.

Vantage is more than a broker. It provides a trusted trading ecosystem, an award-winning mobile trading app, and a faster and simpler trading platform that enables clients to take advantage of trading opportunities. Download the Vantage App on App Store or Google Play.

Be empowered to better capitalise on winning market opportunities when you trade smarter @vantage.

پناہ گزینوں کے لئے عالمی فنڈ جمع کرنے کی سرگرمی کے لئے وینٹیج کی یو این ایچ سی آر سے شراکتداری، ڈالر کے بدلے ڈالر عطیات سے مطابقت

سنگاپور، 1 اگست 2022 /پی آر نیوز وائر/ – وینٹیج، ایک بین الاقوامی کثیر اثاثہ بروکر، یہ اعلان کرتے ہوئے خوش ہے کہ وہ دنیا بھر میں پناہ گزینوں اور اندرونی طور پر بے گھر افراد کی مدد کے لئے اقوام متحدہ کی پناہ گزین ایجنسی یو این ایچ سی آر کی حمایت میں ایک […]

سنگاپور، 1 اگست 2022 /پی آر نیوز وائر/ – وینٹیج، ایک بین الاقوامی کثیر اثاثہ بروکر، یہ اعلان کرتے ہوئے خوش ہے کہ وہ دنیا بھر میں پناہ گزینوں اور اندرونی طور پر بے گھر افراد کی مدد کے لئے اقوام متحدہ کی پناہ گزین ایجنسی یو این ایچ سی آر کی حمایت میں ایک ماہ طویل عطیات مہم شروع کر رہا ہے۔

پناہ گزینوں کے لئے عالمی فنڈ جمع کرنے کی سرگرمی کے لئے وینٹیج کی یو این ایچ سی آر سے شراکتداری، ڈالر کے بدلے ڈالر عطیات سے مطابقت

وینٹیج یو این ایچ سی آر کی جانب سے کی جانے والی انسانی کوششوں کی حمایت کے لئے نئے اور موجودہ دونوں کلائنٹس، ڈالر کے بدلے ڈالر کے تمام عطیات سے مطابقت رکھتی ہوگی۔ عطیہ مہم 30 اگست, یعنی ایک ماہ تک چلے گی اور کلائنٹ کی رائے کی بنیاد پر اس میں توسیع کی جاسکتی ہے۔

یو این ایچ سی آر ایک عالمی تنظیم ہے جس نے گزشتہ 70 سال زندگیاں بچانے، حقوق کے تحفظ اور پناہ گزینوں کے بہتر مستقبل کی فراہمی کے لیے وقف کیے ہیں۔

وینٹیج اور یو این ایچ سی آر کا مشترکہ خیال ہے کہ ہر شخص کو پناہ لینے اور محفوظ پناہ حاصل کرنے کا حق ہے۔ یو این ایچ سی آر کے مطابق تنازعات، تشدد، انسانی حقوق کی خلاف ورزیوں اور ظلم و ستم سے فرار ہونے پر مجبور افراد کی ریکارڈ تعداد پہلی بار 100 ملین کا پریشان کن سنگ میل عبور کر چکی ہے جس میں دنیا بھر میں غذائی عدم تحفظ، موسمیاتی بحران اور افریقہ سے افغانستان تک دیگر ہنگامی صورتحال کو اہم وجوہات کے طور پر اجاگر کیا گیا ہے۔

یو این ایچ سی آر میں پارٹنرشپ منیجر این موئے کا کہنا ہے کہ “اب پہلے سے کہیں زیادہ بین الاقوامی یکجہتی کی ضرورت ہے اور معاشرے کے تمام شعبے مدد کے لیے اپنا کام کر سکتے ہیں۔وینٹیج جیسے نجی شعبے کے شراکت داروں کی مدد سے ہمیں اپنی انسانی کوششوں میں اہم توانائی داخل کرنے میں مدد ملتی ہے اور ہمیں دنیا بھر میں کمزور اور بے گھر کمیونٹیز کو مزید امداد فراہم کرنے میں مدد ملتی ہے۔

فنڈ اکھٹا  کا اقدام وینٹیج کے کارپوریٹ ای ایس جی سفر میں ایک اور سنگ میل ہے، جو اس کے عملے کے درمیان دنیا کو ایک بہتر جگہ بنانے کی اجتماعی خواہش کی وجہ سے تھا۔ یہ عطیہ مہم سارڈینیا، اٹلی میں بلیو کاربن ای ایس جی اقدام میں حصہ لینے میں سپرکار بلونڈی کے ساتھ وینٹیج کی شراکت داری کے ساتھ ساتھ میکلرین ایم ایکس ایکسٹریم ای ٹیم کی کثیر سالہ کفالت کے بعد قریب سے پیروی کرتی ہے۔

وینٹیج میں ای ایس جی سفیر سوفیہ سٹارچیوسکا نے کہا کہ “یہ جاننا بے انتہا طور پر زیادہ پُراثر اور حوصلہ افزا ہے کہ آپ کی سرگرمیاں بہت سے افراد کی ایک  کاوش ہے۔انفرادی سرگرمیوں کے برعکس اجتماعی طاقت کو دیکھنا آسان ہے اور ہم فنڈ ریزنگ کی اس سرگرمی سے یہی حاصل کرنا چاہتے ہیں۔

وینٹیج میں ہم جانتے ہیں کہ بے گھر ہونے اور اجنبی سرزمین پر دوبارہ بسنے کا ذہنی، جذباتی اور جسمانی صدمہ ایک بہت بڑا چیلنج ہے اور ہمیں امید ہے کہ ہمارا اقدام پناہ گزینوں کے تحفظ کے حصول کے لئے ہماری حمایت کو دوگنا کر دے گا اور انہیں ان کی زندگیوں کو تعمیر نو کے قابل بنائے گا۔ یو این ایچ سی آر کے ساتھ مل کر ہمیں امید ہے کہ ہم اپنی مشترکہ رقم کی دیکھ بھال کریں گے۔

ہمارے فنڈ ریزنگ پروگرام کے بارے میں مزید معلومات کے لئے، براہ مہربانی ملاحظہ کریں:
https://donate.unhcr.org/sg/en-sg/vantage

وینٹیج کے بارے میں

وینٹیج ایک عالمی، کثیر اثاثہ بروکر ہے جو کلائنٹس کو فاریکس، کموڈٹیز، انڈیکس اور حصص پر سی ایف ڈی کی تجارت کے لئے ایک چست اور طاقتور سروس تک رسائی کی پیشکش کرتا ہے۔

مارکیٹ کے تجربے کے 10 سال سے زیادہ کے ساتھ۔وینٹیج کے اب 30 سے زائد عالمی دفاتر میں 1000 سے زائد ملازمین/اہلکار ہیں۔

وینٹیج بروکر سے بڑھ کر ہے۔ یہ ایک معتبر تجارتی ماحولیاتی نظام، ایک ایوارڈ یافتہ موبائل ٹریڈنگ ایپ اور ایک تیز رفتار اور آسان تجارتی پلیٹ فارم فراہم کرتا ہے جو کلائنٹس کو تجارتی مواقع سے فائدہ اٹھانے کے قابل بناتا ہے۔ ایپ اسٹور یا گوگل پر وینٹیج ایپ ڈاؤن لوڈ کریں۔

جب آپ ٹریڈ اسمارٹر @ ونٹیج سے مارکیٹ کے مواقع جیتنے میں بہتر فائدہ اٹھانے کے لئے بااختیار بنیں

AOP Health Starts Research for Leukemia Treatment

AOP Health signed an agreement with Leukos Biotech for the further development of a newly discovered chemical substance. With this agreement AOP Health expands the hemato-oncology research area even further and provides additional treatment options for certain leukemia patients in the longer term. Agnes Kohl, Chief Business Officer, AOP Orphan Pharmaceuticals GmbH, Member of the […]

AOP Health signed an agreement with Leukos Biotech for the further development of a newly discovered chemical substance. With this agreement AOP Health expands the hemato-oncology research area even further and provides additional treatment options for certain leukemia patients in the longer term.

Agnes Kohl, Chief Business Officer, AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group

Photo credit: Studio Koekart: Natascha Unkart & Isabelle Köhler

VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) — The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria. The company focuses on research, development and global sales of innovative treatment solutions and specializes in therapies for rare diseases and intensive care. In early July, AOP Health signed an agreement with Leukos Biotech, a spin-off company founded by the Barcelona-based Josep Carreras Leukaemia Research Institute. The agreement signed by AOP Health covers the option for developments of the newly discovered chemical substance within any treatable indication, not limited to oncological or rare diseases.

Luis Ruiz-Avila, Chief Executive Officer Leukos Biotech

Copyright: Albert Mollon

Agreement sets basis for new areas of therapy

At first, AOP Health will focus on the development of treatment options for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Both are special disease types of leukemia that often start in the bone marrow. Agnes Kohl, Chief Business Officer of AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group explains: “Based on positive data, our plan is to expand the development for further orphan indications even outside of AML and MDS at a later stage. With this agreement, we may be able to broaden the portfolio within our therapeutic areas offering even more treatment options for patients.”

Development in cooperation with Leukos

As AOP Health focuses on rare, hemato-oncological cancers and has many years of experience in the development and commercialization of hemato-oncological treatments, the company will drive the further development of the substance in cooperation with Leukos based on a new mode of action. This could potentially turn into a milestone in the treatment of many blood cancer and other cancer patients. Luis Ruiz-Avila, Chief Executive Officer of Leukos Biotech: “We focus on developing new treatments for a wide variety of tumors. We were born to transform excellent science from the Josep Carreras Leukaemia Research Institute into valuable products for cancer patients in need, and this agreement is a very significant step in that direction. We are convinced that AOP Health is the right partner to turn this promising, novel mechanism of action into a clinical reality for the benefit of patients in a wide variety of unmet medical needs”.

About AOP Health

The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as also the healthcare professionals treating them.

About Leukos

Leukos Biotech, SL (Leukos) is a spin-off company from the Josep Carreras Leukaemia Research Institute incorporated in Barcelona in 2015. The company is developing new treatments and diagnostic tools for a wide variety of tumors targeting the serotonin receptor HTR1B, which antitumoral potential was first described and patented by Leukos’ founder Dr. Ruth Risueño in her laboratory at the Josep Carreras Research Institute. Leukos’ main financial support is from private and institutional investors. The main shareholders are Inveready, CDTI Innvierte and the Josep Carreras Foundation. Besides investors’ support, Leukos has received non-dilutive grants and loans from the Catalan Government, the Spanish Government and the European Union in various programs.

About the Josep Carreras Foundation

The Josep Carreras Leukaemia Foundation was established in 1988 with the intention of contributing to finding a definitive cure for this disease. Its efforts are concentrated on four basic areas: administering the Spanish Bone Marrow Donor Registry (REDMO), scientific research, carried out by the Josep Carreras Leukaemia Research Institute, patient guidance through an online patient consultation channel, and reception apartments for patients who need to undergo treatment and have to spend a long time far from home.

About the Josep Carreras Leukaemia Research Institute

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya’s CERCA network, was established in 2010 with the aim of furthering biomedical research and personalised medicine in the field of leukaemia and other onco-hematological diseases. It is the first research centre in Europe exclusively focussed on leukaemia and malignant blood diseases, and one of the very few in the world. The Josep Carreras Institutes has three coordinated but independent scientific campuses: University of Barcelona Hospital Clínic Campus, The Catalan Institute of Oncology/Germans Trias i Pujol Campus, and the Sant Pau – Autonomous University of Barcelona (UAB) Campus

About Inveready

Inveready is a leading alternative asset manager in Spain – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle. Founded in 2008, Inveready counts on 200 active companies, and more than €1bn of assets under management. Inveready has been investing in companies in the Life Sciences sector since 2008. Notable investments in this vertical are Atrys Health (listed on the Spanish market), EDESA Biotech (listed on Nasdaq), AVX Pharma (sold to Aerie Biotech) and PaloBiofarma (licensing agreement with Novartis). Inveready is headquartered in San Sebastian, and has other offices in Barcelona and Madrid. It has been recognized on multiple occasions by ASCRI and Preqin for the return on its funds and transactions (For more information, visit www.inveready.com).

Mag Nina Roth, MAS
nina.roth@aop-health.com

AOP Health
Needs. Science. Trust.

AOP Orphan Pharmaceuticals GmbH
Member of the AOP Health Group

Leopold-Ungar-Platz 2, 1190 Vienna, Austria
aop-health.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f096650f-dbfc-4165-854b-63345d24a713

https://www.globenewswire.com/NewsRoom/AttachmentNg/9aa481fe-91da-4609-8570-2e9a1012c392

Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease  

WALTHAM, Mass and SHANGHAI, China, July 31, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, announced that it has received approval of its Investigational New Drug (IND) application from the National Medical Products […]

WALTHAM, Mass and SHANGHAI, China, July 31, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, announced that it has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) of China for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). The main objective of the Phase 1/2 is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001.

TED is a debilitating vison-threatening autoimmune disease that causes inflammation and fibrosis within the orbit of the eye. With no approved therapies for TED patients in China, treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 is a differentiated humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) intended for the treatment of TED.

“We are proud that the IND application for ZB001 was approved by the NMPA about two months following its submission, highlighting our team’s unique ability to efficiently execute on our development programs,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “We are excited to work with leading clinical experts in China to accelerate the development of ZB001 to address the significant unmet clinical need in thyroid eye disease.”

Zenas BioPharma licensed the exclusive rights to develop, manufacture and commercialize ZB001 (Viridian VRDN-001) and other compounds targeting IGF-1R in non-oncology indications in the greater China area from Viridian Therapeutics, Inc. (Viridian) in October 2020. After submitting an IND for VRDN-001 to the U.S. Food and Drug Administration in October 2021, Viridian initiated a Phase 1/2 clinical trial in December 2021 to evaluate proof of concept in TED patients in North America and released encouraging interim healthy volunteer data suggesting robust activity with excellent safety and tolerability of the candidate product.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and commercialization of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com